TW202042812A - 減少法布瑞氏症患者中之腦血管事件之方法 - Google Patents

減少法布瑞氏症患者中之腦血管事件之方法 Download PDF

Info

Publication number
TW202042812A
TW202042812A TW109101869A TW109101869A TW202042812A TW 202042812 A TW202042812 A TW 202042812A TW 109101869 A TW109101869 A TW 109101869A TW 109101869 A TW109101869 A TW 109101869A TW 202042812 A TW202042812 A TW 202042812A
Authority
TW
Taiwan
Prior art keywords
migalastat
patient
salt
cbv
administered
Prior art date
Application number
TW109101869A
Other languages
English (en)
Chinese (zh)
Inventor
妮娜 史庫班
艾喬莫 拉格斯
Original Assignee
美商阿米庫斯醫療股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69726736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202042812(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商阿米庫斯醫療股份有限公司 filed Critical 美商阿米庫斯醫療股份有限公司
Publication of TW202042812A publication Critical patent/TW202042812A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
TW109101869A 2019-01-22 2020-01-20 減少法布瑞氏症患者中之腦血管事件之方法 TW202042812A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962795524P 2019-01-22 2019-01-22
US62/795,524 2019-01-22

Publications (1)

Publication Number Publication Date
TW202042812A true TW202042812A (zh) 2020-12-01

Family

ID=69726736

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109101869A TW202042812A (zh) 2019-01-22 2020-01-20 減少法布瑞氏症患者中之腦血管事件之方法

Country Status (17)

Country Link
US (1) US20220087993A1 (https=)
EP (2) EP4523750A3 (https=)
JP (2) JP7680356B2 (https=)
AR (1) AR117861A1 (https=)
DK (1) DK3914247T3 (https=)
ES (1) ES3007212T3 (https=)
FI (1) FI3914247T3 (https=)
HR (1) HRP20250078T1 (https=)
HU (1) HUE069934T2 (https=)
LT (1) LT3914247T (https=)
PL (1) PL3914247T3 (https=)
PT (1) PT3914247T (https=)
RS (1) RS66410B1 (https=)
SI (1) SI3914247T1 (https=)
SM (1) SMT202500034T1 (https=)
TW (1) TW202042812A (https=)
WO (1) WO2020154354A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594268B2 (en) * 2018-08-20 2026-04-07 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
TW202408513A (zh) * 2016-07-19 2024-03-01 美商阿米庫斯醫療股份有限公司 治療ert初治的和已經歷ert的患者中之法布瑞氏症

Also Published As

Publication number Publication date
PT3914247T (pt) 2025-01-23
PL3914247T3 (pl) 2025-04-14
EP3914247B1 (en) 2024-11-13
ES3007212T3 (en) 2025-03-19
FI3914247T3 (fi) 2025-02-16
RS66410B1 (sr) 2025-02-28
LT3914247T (lt) 2025-01-27
SI3914247T1 (sl) 2025-03-31
HRP20250078T1 (hr) 2025-03-28
DK3914247T3 (da) 2025-01-27
SMT202500034T1 (it) 2025-03-12
HUE069934T2 (hu) 2025-04-28
EP3914247A1 (en) 2021-12-01
WO2020154354A1 (en) 2020-07-30
JP2022518733A (ja) 2022-03-16
EP4523750A3 (en) 2025-06-11
JP2025128105A (ja) 2025-09-02
US20220087993A1 (en) 2022-03-24
AR117861A1 (es) 2021-09-01
JP7680356B2 (ja) 2025-05-20
EP4523750A2 (en) 2025-03-19

Similar Documents

Publication Publication Date Title
US12599594B2 (en) Treatment of Fabry disease in ERT-naïve and ERT-experienced patients
US12042489B2 (en) Methods of treating Fabry patients having renal impairment
CA3074450C (en) METHODS FOR IMPROVING AND/OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
US20220387462A1 (en) Use Of Migalastat For Treating Fabry Disease In Pregnant Patients
EP3749308B1 (en) Treatment of patients with classic fabry disease with migalastat
TW202042812A (zh) 減少法布瑞氏症患者中之腦血管事件之方法
US20240293387A1 (en) Methods of Treating Fabry Disease in Pediatric Patients
HK40124728A (en) Methods of reducing cerebrovascular events in patients with fabry disease
CA3090499C (en) Use of migalastat for the treatment of patients with classic fabry disease
HK40128496A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
TW202423436A (zh) 改善米加司他之藥物動力學的方法
EA045263B1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри